Debiopharm Releases Results of 3 Key Oncology Compound Programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA

LAUSANNE, Switzerland, April 1, 2019 /PRNewswire/ — Debiopharm, (www.debiopharm.com/debiopharm-international/) a global biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including pre-clinical results of Debio 0123 (Selective WEE1 inhibitor), diagnostic molecular screening for Debio 1347 (FGFR Read more